Mutant Escherichia coli heat-labile enterotoxin [LT(R192G)] enhances protective humoral and cellular immune responses to orally administered inactivated influenza vaccine

Vaccine

Volumn 20, Issue 7-8, 2002, Pages 1019-1029

  Lu, Xiuhua ^a   Clements, J D ^b   Katz, Jacqueline M ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Influenza; Mucosal adjuvant; Oral vaccination

Indexed keywords

ADJUVANT; CD4 ANTIGEN; CYTOKINE; ESCHERICHIA COLI ENTEROTOXIN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INACTIVATED VACCINE; INFLUENZA VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCING CELL; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; HUMORAL IMMUNITY; LOWER RESPIRATORY TRACT INFECTION; LUNG; MOUSE; NONHUMAN; PEYER PATCH; PRIORITY JOURNAL; SERUM; SPLEEN; TH1 CELL; TH2 CELL; UPPER RESPIRATORY TRACT INFECTION; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, VIRAL; BACTERIAL TOXINS; CHOLERA TOXIN; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENTEROTOXINS; ESCHERICHIA COLI PROTEINS; FEMALE; IMMUNOGLOBULIN A; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; MUTATION; VACCINES, INACTIVATED;

EID: 0037081541     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(01)00452-2     Document Type: Article

References (73)

1. Prevention and control of influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
2. Reactogenicity, immunogenicity, and antibody persistence in adults given inactivated influenza virus vaccines-1978
3. Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine
4. The mucosal immune system: From fundamental concepts to vaccine development
5. Strategies for mucosal vaccine development
6. Regulation of the mucosal immune response
7. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children
8. Efficacy of vaccination with live attenuated, cold-adapted, trivalent intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine
9. In elderly persons live attenuated influenza A virus vaccines do not offer an advantage over inactivated virus vaccine in inducing serum or secretory antibodies or local immunologic memory
10. Reduced infectivity of cold-adapted influenza A H1N1 viruses in the elderly: Correlation with serum and local antibodies
11. Immunization against influenza in humans using an oral enteric-coated killed virus vaccine
12. Age-dependent antibody response in mice and humans following oral influenza immunization
13. Human immune responses to influenza virus vaccines administered by systemic or mucosal routes
14. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease
15. Immunization against influenza: Comparison of various topical and parenteral regimens containing inactivated and/or live attenuated vaccines in healthy adults
16. Clinical and immunological characteristics of the emulsion form of inactivated influenza vaccine delivered by oral immunization
17. Use of heat-labile toxin of enterotoxigenic Escherichia coli to facilitate mucosal immunization
18. Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins
19. Immunomodulation using bacterial enterotoxins: Frontlines-topic review
20. Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin
21. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity
22. Relationship between a low toxicity of the mutant A subunit of enterotoxigenic Escherichia coli enterotoxin and its strong adjuvant action
23. Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin
24. Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants
25. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity
26. Mutants of cholera toxin as an effective and safe adjuvant for nasal influenza vaccine
27. Mutants of Escherichia coli heat-labile enterotoxin as an adjuvant for nasal influenza vaccine
28. Genetically derived toxoids for use as vaccines and adjuvants
29. The role of cAMP in mucosal adjuvanticity of Escherichia coli heat-labile enterotoxin (LT)
30. The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity
31. Genetically detoxified mutants of heat-labile toxin from Escherichia coli are able to act as oral adjuvants
32. Heat-labile enterotoxin from Escherichia coli as an adjuvant for oral influenza vaccination
33. Rotavirus 2/6 virus like particles administered intranasally with cholera toxin, Escherichia coli heat-labile toxin (LT), and LT-R192G induce protection from rotavirus challenge
34. Effectiveness of intranasal immunization with HIV-gp160 and an HIV-1 env CTL epitope peptide (E7) in combination with the mucosal adjuvant LT(R192G)
35. Intranasal administration of 2/6-rotavirus-like particles with mutant Escherichia coli heat-labile toxin (LT-R192G) induces antibody-secreting cell responses but not protective immunity in gnotobiotic pigs
36. Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA
37. Mucosal immunization of mice using CpG DNA and/or mutants of the heat-labile enterotoxin of Escherichia coli as adjuvants
38. LT(R192G), a non-toxic mutant of the heat-labile enterotoxin of Escherichia coli, elicits enhanced humoral and cellular immune responses associated with protection against lethal oral challenge with Salmonella spp.
39. Adjuvant activity of a nontoxic mutant of Escherichia coli heat-labile enterotoxin on systemic and mucosal immune responses elicited against a heterologous antigen carried by a live Salmonella enterica serovar typhimurium vaccine strain
40. Effectiveness of a vaccine composed of heat-killed Candida albicans and a novel mucosal adjuvant, LT(R192G), against systemic candidiasis
41. The adjuvants MF59 and LT-K63 enhance the mucosal and systemic immunogenicity of subunit influenza vaccine administered intranasally in mice
42. Intranasal immunization of mice with influenza vaccine in combination with the adjuvant LT-R72 induces potent mucosal and serum immunity which is stronger than that with traditional intramuscular immunization
43. Mucosal immunogenicity and adjuvant activity of the recombinant A subunit of the Escherichia coli heat-labile enterotoxin
44. Effectiveness and safety of mutant Escherichia coli heat-labile enterotoxin (LT H44A) as an adjuvant for nasal influenza vaccine
45. Oral immunization with influenza virus in biodegradable microspheres
46. Induction, persistence and strain specificity of haemagglutinin-specific secretory antibodies in lungs of mice after intragastric administration of inactivated influenza virus vaccines
47. Antibody responses and protection in mice immunized orally against influenza virus
48. Adjuvant activity of the heat-labile enterotoxin from enterotoxigenic Escherichia coli for oral administration of inactivated influenza virus vaccine
49. Oral administration of influenza vaccine in combination with the adjuvants LT-K63 and LT-R72 induces potent immune responses comparable to or stronger than traditional intramuscular immunization
50. Genetic stability of A/Ann Arbor/6/60 cold-mutant (temperature-sensitive) live influenza virus genes: Analysis by oligonucleotide mapping or recombinant vaccine strains before and after replication in volunteers
51. A nonionic block co-polymer adjuvant (CRL1005) enhances the immunogenicity and protective efficacy of inactivated influenza vaccine in young and aged mice
52. A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells
53. A simple method of estimating fifty per cent endpoints
54. Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection
55. Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: Differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells
56. Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin
57. Th2 responses to inactivated influenza virus can be converted to Th1 responses and facilitate recovery from heterosubtypic virus infection
58. A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity
59. Helper T cell subsets for immunoglobulin A responses: Oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues
60. Helper Th1 and Th2 cell responses following mucosal or systemic immunization with cholera toxin
61. The in vitro production of cytokines by mucosal lymphocytes immunized by oral administration of keyhole limpet hemocyanin using cholera toxin as an adjuvant
62. Cholera toxin adjuvant greatly promotes antigen priming of T cells
63. Nasal immunization induces Haemophilus influenza-specific Th1 and Th2 responses with mucosal IgA and systemic IgG antibodies for protective immunity
64. Interplay of cytokines and adjuvants in the regulation of mucosal and systemic HIV-specific CTL
65. Mucosal immunoadjuvant activity of recombinant Escherichia coli heat-labile enterotoxin and its B subunit: Induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with influenza virus surface antigen
66. Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin
67. Phase 1 evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin in adult volunteers
68. Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing Escherichia coli heat-labile toxin as a mucosal adjuvant
69. New mucosal adjuvant safe in humans
70. Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection
71. Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens
72. Potency of a genetically detoxified mucosal adjuvant derived from the heat-labile enterotoxin of Escherichia coli (LTK63) is not adversely affected by the presence of preexisting immunity to the adjuvant